The product adopts the Type A and Type B influenza viral stain (referred to as “flu”) that recommended by WHO. The product is obtained through culture, harvesting influenza fluid, virus inactivation, concentration, purification and splitting after inoculating the chick embryos by strains respectively. It is light opal fluid.

The product is prepared with HBsAg purified from the recombinant Hansenula polymorpha and aluminum adjuvant. The product is an opalescent suspension, it may separate into layers due to precipitation which easily disperses by shaking.

The product is prepared by extracting and purifying the polysaccharide antigens of group A, C, Y, and W135 Neisseria meningitidis from the cultured fluid of such Neisseria meningitidis, then mixing the antigen with suitable stabilizing antigen andfreeze drying the product. The product is in white loose chunks, after reconstitution using the provided diluent, the product is a colorless and transparent liquid.

Vaccination subjects: The vaccine is approved for use in people aged 3 and above, especially in vulnerable people and high risk population for influenza complications, such as children, the elderly, the weak and people in influenza epidemic areas.

Indication and usage: After vaccination, the vaccine can stimulate the body to produce the immunity of anti-influenza virus; it is used for preventing influenza caused by vaccine related type of influenza virus.

Vaccination subjects:Children whose age are over 2 years old and adults.